Accuity vs Regard
Two Revenue Integrity & Pre-Bill Review vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Accuity | Regard | |
|---|---|---|
| Pricing model | Contingency (pay from recoveries) · 60-day pilot, no upfront fees | Not published · Health system contracts |
| Speed to go live | Chart data feed plus 60-day pilot | System-wide EHR embed with chart data access |
| Automation model | Tech-enabled service · AI triage, physician-performed reviews | AI copilot · diagnosis suggestions inside the chart |
| Built for | Enterprise systems | Enterprise systems |
| Security posture | HITRUST | No certifications published |
| Company maturity | 10 yrs (est. 2016) | 9 yrs (est. 2017) |
| Financial backing | Undisclosed | $80M+ · Series B |
| Named customers | 1 named | 4 named |
| Published results | Specific numbers public | No public numbers |
| Documented integrations | None documented | 1 listed |
| Third-party validation | None found | None found |
Bottom line
- Pick Accuity if you want guaranteed inpatient revenue capture from a physician-staffed service rather than another tool for your own team.
- Pick Regard if you run a hospital or health system and want an EHR-embedded copilot that surfaces missed diagnoses and drafts documentation for clinicians.
Accuity
Physician-led pre-bill chart review that recovers earned revenue
- Founded
- 2016
- HQ
- Mount Laurel, NJ
- Stage
- n/a
- Raised
- n/a
What it does
- Post-discharge, pre-bill second-level chart review
- Amplifi AI trained on 7M+ chart outcomes
- 185 multi-specialty physicians review flagged cases
- DRG, CC/MCC, and quality metric capture
- Medicaid expertise across 38 states
- Compliance oversight with 1.5% final denial rate
Where it's strong
- Runs after your CDI and coding teams finish, so it adds a safety net without changing their workflow.
- Scale is proven: 400+ hospital sites, 4 of the top 10 US health systems, and $3.3B in client revenue lift.
- Performance-based pricing with a 60-day pilot and no upfront fees keeps buyer risk low.
What buyers should weigh
- It is a service engagement, not software your team operates, so capability does not transfer in-house.
- Fees come out of recovered revenue, which costs more at scale than licensing a tool.
- Focused on inpatient pre-bill review; it does not address front-end or denial workflows.
Named customers
Temple Health
Regard
AI that surfaces undocumented diagnoses in the workflow
- Founded
- 2017
- HQ
- Los Angeles, CA
- Stage
- Series B
- Raised
- $80M+
What it does
- Reviews the full patient chart inside the EHR
- Surfaces missed or undocumented diagnoses to clinicians
- Drafts clinical notes with supporting evidence linked
- Runs concurrently during the stay, not post-discharge
- Improves documentation for both revenue and quality metrics
Where it's strong
- Works concurrently inside the clinician's Epic workflow, so diagnoses are captured while the physician can still act on them, unlike post-discharge review tools.
- Multi-year, system-wide proof: Sentara scaled to all 12 hospitals after 2-4x ROI, and Banner rolled it toward 33 hospitals.
- Cedars-Sinai is investor, development partner, and customer, giving unusual clinical depth for a company this size.
What buyers should weigh
- Requires physician adoption to deliver value, a harder change-management lift than back-office tools your clinicians never see.
- Smaller war chest (roughly $80M raised) than several competitors chasing the same documentation dollars.
- Value proposition mixes clinical decision support with revenue capture; make sure your compliance team is comfortable with how diagnosis suggestions are framed.
Named customers
Cedars-Sinai · Banner Health · Sentara Health · WakeMed Health & Hospitals
Integrations
Compare against the rest of Revenue Integrity & Pre-Bill Review
Deciding between these two?
First Pass tracks Revenue Integrity & Pre-Bill Review every week: funding, launches, and what changed since this page was written.